FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:910-912 September 20, 2001 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lewis, E. J. Related Article by Brenner, B. M. Related Article by Parving, H.-H. PubMed Citation

The prevalence of end-stage renal disease is increasing at an alarming rate. In 2000, chronic kidney failure developed in over 90,000 people in the United States; the current population of patients on dialysis numbers about 300,000, and 80,000 patients are living with transplanted kidneys. Both the prevalence and the incidence of end-stage renal disease are approximately twice what they were 10 years ago.¹ Indeed, in 2000, the number of patients with newly diagnosed renal failure exceeded the number who died of any single type of cancer except lung cancer. Nephropathy due to type 2 diabetes accounts for almost all of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Xu, Z.-G., Miao, L.-N., Cui, Y.-C., Jia, Y., Yuan, H., Wu, M. (2009). Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli. Nephrol Dial Transplant 24: 1744-1752 [Abstract] [Full Text]  
• Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., Rodby, R. A. (2008). A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 23: 1216-1223 [Abstract] [Full Text]  
• Navarro-Gonzalez, J. F., Mora-Fernandez, C. (2008). The Role of Inflammatory Cytokines in Diabetic Nephropathy. J. Am. Soc. Nephrol. 19: 433-442 [Abstract] [Full Text]  
• Sedor, J. R. (2006). Frontiers in Diabetic Nephropathy: Can We Predict Who Will Get Sick?. J. Am. Soc. Nephrol. 17: 336-338 [Full Text]  
• Navarro, J. F., Mora, C., Muros, M., Garcia, J. (2005). Additive Antiproteinuric Effect of Pentoxifylline in Patients with Type 2 Diabetes under Angiotensin II Receptor Blockade: A Short-Term, Randomized, Controlled Trial. J. Am. Soc. Nephrol. 16: 2119-2126 [Abstract] [Full Text]  
• Codreanu, I., Perico, N., Remuzzi, G. (2005). Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection?. J. Am. Soc. Nephrol. 16: S34-S38 [Abstract] [Full Text]  
• Jarvis, S. C (2004). VALUE, blood pressure and diabetes -- what can we learn?. British Journal of Diabetes & Vascular Disease 4: 418-420 [Abstract]  
• Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R., Gabriel, S., Carita, P., Rodby, R. A., de Zeeuw, D., Parving, H.-H. (2004). Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease. Diabetes Care 27: 1897-1903 [Abstract] [Full Text]  
• Zandbergen, A. A.M., Baggen, M. G.A., Lamberts, S. W.J., Bootsma, A. H., de Zeeuw, D., Ouwendijk, R. J.Th. (2003). Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial. ANN INTERN MED 139: 90-96 [Abstract] [Full Text]  
• Benigni, A., Zoja, C., Corna, D., Zatelli, C., Conti, S., Campana, M., Gagliardini, E., Rottoli, D., Zanchi, C., Abbate, M., Ledbetter, S., Remuzzi, G. (2003). Add-On Anti-TGF-{beta} Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. J. Am. Soc. Nephrol. 14: 1816-1824 [Abstract] [Full Text]  
• Hostetter, T. H., Lising, M. (2003). National Kidney Disease Education Program. J. Am. Soc. Nephrol. 14: S114-116 [Abstract] [Full Text]  
• Siragy, H. M., Awad, A., Abadir, P., Webb, R. (2003). The Angiotensin II Type 1 Receptor Mediates Renal Interstitial Content of Tumor Necrosis Factor-{alpha} in Diabetic Rats. Endocrinology 144: 2229-2233 [Abstract] [Full Text]  
• Nangaku, M., Miyata, T., Sada, T., Mizuno, M., Inagi, R., Ueda, Y., Ishikawa, N., Yuzawa, H., Koike, H., van Ypersele de Strihou, C., Kurokawa, K. (2003). Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model. J. Am. Soc. Nephrol. 14: 1212-1222 [Abstract] [Full Text]  
• August, P. (2003). Initial Treatment of Hypertension. NEJM 348: 610-617 [Full Text]  
• Harris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., Lohr, K. N. (2003). Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 138: 215-229 [Abstract] [Full Text]  
• Campbell, R. C., Ruggenenti, P., Remuzzi, G. (2002). Halting the Progression of Chronic Nephropathy. J. Am. Soc. Nephrol. 13: S190-195 [Abstract] [Full Text]  
• Star, R., Hostetter, T., Hortin, G. L. (2002). New Markers for Kidney Disease. Clin. Chem. 48: 1375-1376 [Full Text]  
• Lorenzo, O., Ruiz-Ortega, M., Suzuki, Y., Ruperez, M., Esteban, V., Sugaya, T., Egido, J. (2002). Angiotensin III Activates Nuclear Transcription Factor-{kappa}B in Cultured Mesangial Cells Mainly via AT2 Receptors: Studies with AT1 Receptor-Knockout Mice. J. Am. Soc. Nephrol. 13: 1162-1171 [Abstract] [Full Text]  
• Hilgers, K. F., Mann, J. F. E. (2002). ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease. J. Am. Soc. Nephrol. 13: 1100-1108 [Full Text]  
• Blankfield, R. P., Ceriello, A., Motz, E., Walser, M., Lewis, E. J., Brenner, B. M., the RENAAL Study Investigators, , Parving, H.-H., the Irbesartan in Patients with Type 2 Diabetes an, (2002). Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection. NEJM 346: 705-707 [Full Text]  
• Rossing, K., Christensen, P. K., Jensen, B. R., Parving, H.-H. (2002). Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study. Diabetes Care 25: 95-100 [Abstract] [Full Text]  
• (2001). ARBs Can Prevent Renal-Disease Progression in Type 2 Diabetics. Journal Watch Cardiology 2001: 2-2 [Full Text]  
• (2001). Angiotensin-Receptor Antagonists for Diabetic Nephropathy. JWatch General 2001: 1-1 [Full Text]